What's in a Placebo?
Drug companies are allowed to use (and do often use) active placebos in their studies. An active placebo is one that is biologically active, rather than inert.
Recently, I was reading some medical studies and I started to wonder about who makes placebos and what's in them.
The reason I began wondering about this is that one of the medical studies I'd been reading involved a medical condition for which sugar (supposedly the main ingredient of placebos) would be anything but biologically inert. I thought to myself: "Okay, certainly the doctors would know that and would choose a sugar-free placebo for the study." But when I read the study I couldn't find an ingredients list for the placebo. Maybe it was a sugar pill. Maybe not. We'll never know.
Then I started to wonder: Who makes placebos? Where do they come from? Is there a widely used "standard placebo" that scientists typically use in studies? What does it contain, exactly? And so on.
Let me skip right to the punch line. It turns out the drug companies (the very people who perform and/or fund the efficacy studies FDA relies on when granting new drug approvals) manufacture their own placebos—and aren't required to list the ingredients.
One reason this is potentially disturbing is that drug companies are allowed to use (and do often use) active placebos in their studies. An active placebo is one that is biologically active, rather than inert.
"But wait," you're probably saying. "Isn't the whole point of a placebo that it's biologically inert, by definition?"
You'd think so. But you'd be wrong. Active placebos are designed to mimic the side-effects of drugs under study. So for example, if a new drug is known (or thought by the drug company) to produce dry mouth, the drug company might use a placebo containing ingredients that produce dry-mouth. That way, of course, they can say things in their ads like "[drug name] has a low occurrence of side effects, such as dry mouth, which occurred about as often as they did with placebo."
In a 2010 study by Beatrice A. Golomb, M.D., Ph.D. (and colleagues), published in the Annals of Internal Medicine (19 October 2010;153(8):532-535), some 150 recent placebo-controlled trials were examined to see how many of them listed placebo ingredients. Only eight percent of trials using placebos in pill form (the majority of trials) disclosed ingredients. Overall, three quarters of studies failed to report placebo ingredients.
One of the trials in the Golomb study involved a heart drug. Over 700 patients participated. In a subgroup of patients that had recently experienced a heart attack, the drug in question (clofibrate) was no better than placebo in extending patients' lives. But the placebo was actually quite effective, reducing the group's mortality rate by more than half. However: the placebo was olive oil. And olive oil is known to fight heart disease.
Carelessly chosen placebos can also have a harmful effect. Dr. Golomb tells of receiving a call from HIV researchers whose drug study had to be aborted because the placebo group was "dropping like flies." The placebo contained lactose. It's well known that lactose intolerance is higher for HIV patients than for the general population.
It's inconceivable (to me, at least) that there are no laws requiring drug companies to list placebo ingredients. The fact that drug companies can formulate their own placebos (some of which are biologically active) and not list the ingredients, in research aimed at getting approvals from FDA, is outrageous.
It seems obvious that researchers (whether associated with drug companies or not) need to agree on a standard placebo of some kind (or at least standards for placebos).
FDA needs to review its policies on placebos and either outlaw "active placebos" or rigorously define acceptable conditions for their use.
When I say FDA needs to review its policies on placebos, I'm referring to such (ongoing) practices as letting drug companies de-enroll study subjects from studies based on individuals' sensitivity to placebos. (Drug makers usually begin a study with a two-week "washout period" during which time potential subjects take either a placebo, or nothing. Subjects who respond to the placebo can be summarily taken out of the study before it begins in earnest.)
The current anarchy that prevails with regard to placebos calls into question the reliability not just of drug-company research but of virtually every placebo-controlled study ever done. Which is a hell of a thing to have to say, or even think about.
Someone pass me the Tic-Tacs.
Former president of the ACLU Nadine Strossen discusses whether our society should always defend free speech rights, even for groups who would oppose such rights.
- Former ACLU president Nadine Strossen understands that protecting free speech rights isn't always a straightforward proposition.
- In this video, Strossen describes the reasoning behind why the ACLU defended the free speech rights of neo-Nazis in Skokie, Illinois, 1977.
- The opinions expressed in this video do not necessarily reflect the views of the Charles Koch Foundation, which encourages the expression of diverse viewpoints within a culture of civil discourse and mutual respect.
Want to be smarter than you were yesterday? Learn to have better conversations using these 3 design principles.
- What is a great conversation? They are the ones that leave us feeling smarter or more curious, with a sense that we have discovered something, understood something about another person, or have been challenged.
- There are 3 design principles that lead to great conversations: humility, critical thinking, and sympathetic listening.
- Critical thinking is the celebrated cornerstone of liberalism, but next time you're in a challenging and rewarding conversation, try to engage sympathetic listening too. Understanding why another intelligent person holds ideas that are at odds with your own is often more enlightening than merely hunting for logic errors.
A consortium of scientists and engineers have proposed that the U.S. and Mexico build a series of guarded solar, wind, natural gas and desalination facilities along the entirety of the border.
- The proposal was recently presented to several U.S. members of Congress.
- The plan still calls for border security, considering all of the facilities along the border would be guarded and connected by physical barriers.
- It's undoubtedly an expensive and complicated proposal, but the team argues that border regions are ideal spots for wind and solar energy, and that they could use the jobs and fresh water the energy park would create.
The reason one diet does not suit all may be found in our guts.